<DOC>
	<DOCNO>NCT00553150</DOCNO>
	<brief_summary>RATIONALE : Everolimus may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , temozolomide , work different way stop growth cancer cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving everolimus together temozolomide radiation therapy may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose everolimus give together temozolomide radiation therapy treat patient newly diagnose glioblastoma .</brief_summary>
	<brief_title>Everolimus , Temozolomide , Radiation Therapy Treating Patients With Newly Diagnosed Glioblastoma</brief_title>
	<detailed_description>OBJECTIVES : - To determine maximum tolerate dose ( MTD ) everolimus combination temozolomide 3D-conformal radiotherapy intensity-modulated radiotherapy ( IMRT ) follow adjuvant temozolomide without everolimus patient newly diagnose glioblastoma . ( Mayo Clinic Rochester [ MCR ] AND Mayo Clinic Jacksonville [ MCJ ] patient ) ( Phase I ) - To assess describe adverse event everolimus combination temozolomide 3D-conformal radiotherapy IMRT follow adjuvant temozolomide without everolimus patient newly diagnose glioblastoma . ( MCR MCJ patient ) ( Phase I ) - To assess treatment effectiveness everolimus combination temozolomide 3D-conformal radiotherapy IMRT follow adjuvant temozolomide without everolimus , progression , patient newly diagnose glioblastoma . ( North Central Cancer Treatment Group [ NCCTG ] patient ) ( Phase II ) - To characterize toxicity everolimus combination temozolomide 3D-conformal radiotherapy IMRT follow adjuvant temozolomide without everolimus patient newly diagnose glioblastoma . ( NCCTG patient ) ( Phase II ) - Evaluate whether suppression fludeoxyglucose F18 ( 18FDG ) uptake tumor normal brain use determine biologically effective dose efficient penetration everolimus blood-brain barrier . ( MCR MCJ patient ) ( Phase I ) - Correlate everolimus level 18FDG uptake suppression tumor normal brain . ( MCR MCJ patient ) ( Phase I ) - Assess relationship efficacy endpoint ( i.e. , survival , progression-free survival , response ) change 3'-deoxy-3'- [ 18F ] fluorothymidine ( 18F-FLT ) uptake patient treat MCR . ( NCCTG patient ) ( Phase II ) - Assess relationship efficacy endpoint ( i.e. , survival , progression-free survival , response ) , phospho-Akt , PTEN status , MGMT expression promoter methylation status . ( NCCTG patient ) ( Phase II ) - Assess relationship efficacy endpoint ( i.e. , survival , progression-free survival , response ) baseline gene expression signatures paraffin embed pre-treatment tumor sample . ( NCCTG patient ) ( Phase II ) - Correlate gene expression paraffin frozen sample . ( NCCTG patient ) ( Phase II ) - Evaluate potential mechanism therapy resistance recurrent tumor sample obtain time surgery recurrent disease . ( Phase I II ) OUTLINE : This multicenter , phase I dose-escalation study everolimus follow phase II study . - Phase I ( Mayo Clinic Rochester [ MCR ] AND Mayo Clinic Jacksonville [ MCJ ] ONLY ) : - Concurrent therapy ( course 1 2 ) : Patients receive oral everolimus weekly week 1-7 1-8 oral temozolomide daily week 2-7 3-8 . Patients also undergo radiotherapy 5 day week either week 2-7 3-8 . Four six week later , patient proceed adjuvant therapy . This rest period define course 2 . - Adjuvant therapy everolimus temozolomide ( course 3-8 ) : Patients receive oral everolimus day 1 , 8 , 15 , 22 oral temozolomide day 1-5 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . - Adjuvant therapy everolimus alone ( course 9 subsequent course ) : Patients receive oral everolimus day 1 , 8 , 15 , 22 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . - Phase II ( Open MCR center ONLY ) ( All North Central Cancer Treatment Group [ NCCTG ] center close accrual 02/17/11 ) : - Concurrent therapy ( course 1 2 ) : Patients receive oral everolimus oral temozolomide 3D-conformal radiotherapy IMRT phase I . Patients undergo 4-6 week rest period course 2 proceed adjuvant therapy . - Adjuvant therapy everolimus temozolomide ( course 3-8 ) : Patients receive oral everolimus oral temozolomide phase I . - Adjuvant therapy everolimus alone ( course 9 subsequent course ) : Patients receive oral everolimus phase I . All patient undergo fludeoxyglucose ( FDG ) - fluorothymidine-labeled PET/CT scan baseline periodically treatment . Patients undergo blood sample collection periodically pharmacological study . Samples analyze everolimus blood level correlate 18FDG uptake suppression tumor normal brain via LC-MSMS . Previously collect tumor tissue analyze protein biomarkers include PTEN gene expression level via fluorescence situ hybridization ( FISH ) immunohistochemistry ( IHC ) phosphorylation Ser473 Ser308 Akt MGMT expression promoter methylation via IHC . Samples also analyze DNA sequence . Some sample bank future study . After completion study treatment , patient follow every 2 month 1 year , every 3 month 1 year , every 6 month 3 year . PROJECTED ACCRUAL : A total 138 patient ( 24 patient phase I 114 patient phase II ) accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Glioblastoma multiforme ( grade 4 astrocytoma ) Other grade 4 astrocytoma variant ( e.g. , giant cell ) No grade 4 oligodendrogliomas oligoastrocytomas Gliosarcoma Newly diagnose disease Measurable disease ≥ 1 cm³ ( phase I patient ) Some patient may register protocol NCCTG947252 No oligodendrogliomas oligoastrocytomas PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status 02 ANC ≥ 1,500/μL Hemoglobin ≥ 9.0 g/dL Platelet count ≥ 100,000/μL Total bilirubin ≤ 2.5 x institutional upper limit normal ( ULN ) Serum total cholesterol &lt; 350 mg/dL Serum total triglyceride &lt; 400 mg/dL AST ≤ 2.5 x ULN Creatinine ≤ 1.5 x ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 60 day completion study therapy Must willing undergo 2 mandatory research PET PET/CT scan ( MCR MCJ patient phase I MCR patient phase II ) Must willing abstain eat drink grapefruit grapefruit juice study treatment Must willing follow diet low fat cholesterol take everolimus Must willing imaging scan submit central review Ability understand willingness sign write informed consent Exclusion criterion : Other active cancer require therapy control disease prior cancer diagnosis pose great 30 % risk death within next 2 year Gastrointestinal tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption , active uncontrolled peptic ulcer disease Uncontrolled intercurrent illness include , limited , follow : Ongoing , uncontrolled , active ( acute chronic ) infection disorder Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness/social situation would limit compliance study requirement Severely impaired lung function Uncontrolled diabetes ( fast serum glucose &gt; 2 x ULN ) OR diabetes would interfere performance FDGPET/CT FDGPET scan Liver disease ( e.g. , cirrhosis , chronic active hepatitis , chronic persistent hepatitis , history hepatitis B ) Known HIV positivity Positive hepatitis B antigen ( HBsAg ) hepatitis C serology ( HCV ) test Any history allergy intolerance dacarbazine ( DTIC ) Significant traumatic injury within past 21 day Severe allergy sulfa medication Inability tolerate levofloxacin dapsone pentamidine ( inhaled IV ) PRIOR CONCURRENT THERAPY : Inclusion criterion : At least 1 week , 6 week since prior surgical resection biopsy Must comply antibiotic prophylaxis either trimethoprim/sulfamethoxazole ( daily 3 time per week ) , oral dapsone ( daily ) combine daily levofloxacin , monthly pentamidine ( inhaled IV ) combine daily levofloxacin Exclusion criterion : Prior chemotherapy brain tumor Prior temozolomide mTOR inhibitor therapies Any prior cranial radiotherapy Planned immunization attenuate live vaccine ≤ 7 day prior study period At least 21 day since prior major surgery ( exclude neurosurgical biopsy , resection brain tumor , treatment immediate postneurosurgical complication [ e.g. , intracranial hematoma ] ) Concurrent prior treatment cancer investigational agent Concurrent enzymeinducing anticonvulsant ( EIACs ) strong inducer CYP3A4 ( i.e. , carbamazepine , phenytoin , phenobarbital/primidone , rifabutin , rifampin , St. John 's wort ) Concurrent therapeutic dos warfarin Low molecular weight heparin allow Concurrent systematic leukocyte growth factor ( e.g. , GCSF GMCSF ) , except treatment severe neutropenia Concurrent drug substance know inhibit induce CYP3A Other concurrent chronic treatment immunosuppressive agent except dexamethasone Other concurrent anticancer agent Concurrent live vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult subependymal giant cell astrocytoma</keyword>
</DOC>